Photoactive assemblies of organic compounds and biomolecules: drug-protein supramolecular systems by Vayá Pérez, Ignacio et al.
 Document downloaded from: 
 
This paper must be cited as:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The final publication is available at 
 
 
Copyright 
 
Additional Information 
 
http://dx.doi.org/10.1039/C3CS60413F
http://hdl.handle.net/10251/51393
Royal Society of Chemistry
Vayá Pérez, I.; Lhiaubet-Vallet, VL.; Jiménez Molero, MC.; Miranda Alonso, MÁ. (2014).
Photoactive assemblies of organic compounds and biomolecules: drug-protein
supramolecular systems. Chemical Society Reviews. 43:4102-4122.
doi:10.1039/C3CS60413F.
1 
 
Photoactive Assemblies of Organic Compounds and Biomolecules: Drug/Protein 
Supramolecular Systems 
 
Ignacio Vayá, Virginie Lhiaubet-Vallet, M. Consuelo Jiménez* and Miguel A. 
Miranda* 
Departamento de Química/Instituto de Tecnología Química UPV-CSIC. Universitat 
Politècnica de València, Camino de Vera s/n, Apdo 22012, E-46071 Valencia (Spain). 
mcjimene@qim.upv.es; mmiranda@qim.upv.es 
Keywords: 1-acid glycoproteins, fluorescence, laser flash photolysis, serum albumins, 
photoreactivity, protein binding. 
Dedicated to the memory of Prof. Nicholas J. Turro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Abstract 
The properties of singlet and triplet excited states are strongly medium-dependent. 
Hence, these species constitute valuable tools as reporters to probe compartmentalised 
microenvironments, including drug@protein supramolecular systems. In the present 
review, the attention is focused on the photophysical properties of the probe drugs 
(rather than those of the protein chromophores) using transport proteins (serum 
albumins and 1-acid glycoproteins) as hosts. Specifically, fluorescence measurements 
allow investigating the structural and dynamic properties of biomolecules or their 
complexes. Thus, the emission quantum yields and the decay kinetics of the drug singlet 
excited states provide key information to determine important parameters such as the 
stoichiometry of the complex, the binding constant, the relative degrees of occupancy of 
the different compartments, etc. Application of the FRET concept allows determining 
donor-acceptor interchromophoric distances. In addition, anisotropy measurements can 
be related to the orientation of the drug within the binding sites, where the degrees of 
freedom for conformational relaxation are restricted. Transient absorption spectroscopy 
is also a potentially powerful tool to investigate the binding of drugs to proteins, where 
formation of encapsulated triplet excited states is favoured over other possible processes 
leading to ionic species (i. e. radical ions), and their photophysical properties are 
markedly sensitive to the microenvironment experienced within the protein binding 
sites. Even under aerobic conditions, the triplet lifetimes of protein-complexed drugs are 
remarkably long, which provides a broad dynamic range for identification of distinct 
triplet populations or for chiral discrimination. Specific applications of the laser flash 
photolysis technique include the determination of drug distribution among the bulk 
solution and the protein binding sites, competition of two types of proteins to bind a 
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drug, occurrence of drug-drug interactions within protein binding sites, enzymatic-like 
activity of the protein or determination of enantiomeric compositions.  
 The use of proteins as supramolecular hosts modifies the photoreactivity of 
encapsulated substrates by providing protection against oxygen or other external 
reagents, by imposing conformational restrictions in the binding pockets, or by 
influencing the stereochemical outcome. In this review, a selected group of examples is 
presented including decarboxylation, dehalogenation, nucleophilic addition, 
dimerisation, oxidation, Norrish type II reaction, photo-Fries rearrangement and 6 
electrocyclisation. 
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1. Introduction  
Transport proteins are very abundant in plasma and
 
are responsible for a variety of 
relevant processes;
1-4
 one of their most important physiological roles is to carry 
different agents (i.e. drugs or metabolites) in the bloodstream for their selective delivery 
to specific targets.
2, 5
 In this context, the binding of drugs to transport proteins is a key 
process, since it is involved in the modulation of drugs solubility in plasma, toxicity, 
susceptibility to oxidation, and in vivo half-life.
2-4
 For these reasons, protein binding has 
been studied for years with different techniques in order to understand their functions 
and to disclose the structural basis for designing new therapeutic agents.
6
  
 When drugs are bound to proteins, their time of action is prolonged by retarding 
metabolisation. The extent of binding depends on total drug concentrations and on its 
affinity to the protein. The process is usually reversible, and equilibrium is established 
between bound and free drug. Only unbound drugs are pharmacologically active, so a 
high protein binding affinity results in improved solubility and increased half-life. 
Conversely, a low binding affinity is associated with limited ability to perfuse tissues 
and to reach the site of action.  
 Human serum albumin (HSA) is synthesised and secreted by the liver. Its primary 
structure consists of a single chain of 585 amino acid residues, containing one 
tryptophan, 17 disulfide bridges, and one free cysteine. As much as 67% of the 
secondary structure is formed by a -helix of six turns; the three-dimensional structure 
can be described in terms of three domains, each of them constituted by two 
subdomains.
7
 Bovine serum albumin (BSA) is also among the most studied and 
commonly used proteins; it presents 76% sequence similarity to HSA, but contains two 
Trp residues instead of one. In general, the structural differences observed between both 
albumins are conservative in nature. Owing to the similarity between HSA and BSA, 
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many studies on the drug-protein binding process have used BSA as a model.
8-10
 
Usually, small organic molecules bind primarily to two high-affinity sites of albumins, 
with typical association constants in the range of 10
4–106 M-1. According to Sudlow´s 
nomenclature, they are called site I and site II.
11
 In addition, lower-affinity sites are 
often populated. 
 Likewise, 1-acid glycoproteins are plasma transport proteins synthesised in the 
liver. They constitute one of the major types of acute phase proteins, and hence their 
serum concentration increases in response to a systemic tissue injury, inflammation or 
infection. In humans, HAG (human 1-acid glycoprotein) consists of one polypeptide 
chain with 183 amino acids and has a molecular weight of 44 kDa. This protein exhibits 
a high degree of glycosylation, with carbohydrates accounting for ∼45% of its total 
mass. For HAG, up to seven binding sites have been described; however, most small 
organic molecules bind almost exclusively to one of them. This high-affinity site is 
large and flexible, where the areas for basic, acid, and neutral drugs overlap.
12-20
 As 
regards the bovine analogue (BAG), binding of some ligands has been studied, and the 
results reveal substantial overlap of a basic drug and a steroid hormone binding sites, 
which significantly affect each other. The hydrophobic nature of the binding pockets on 
the two glycoproteins is similar; however, their microviscosities are markedly 
different.
21
 
 In view of the importance of the drug-protein binding process, a number of 
techniques have been developed for investigation of this issue. They include 
equilibrium dialysis, HPLC, chromatography, ultrafiltration, spectrophotometry, 
calorimetry, circular dichroism, capillary electrophoresis, NMR, etc.
22-33 
The main 
limitations of these methodologies are related to sensitivity, interferences, diffusion 
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problems or lack of reproducibility arising from a complicated workup. In the present 
review, the attention is focused on photophysical techniques, which combine steady-
state and time-resolved fluorescence (including anisotropy experiments) with transient 
absorption spectroscopy. In addition, modified photoreactivity of some ligands 
encapsulated within protein binding sites is discussed.  
 As the review is dedicated to the memory of N. J. Turro, it is pertinent to say that 
he made relevant contributions in related fields. They encompass from chiral protein 
scissors to analysis of protein-surfactant interactions or singlet oxygen production 
within proteins.
34-39
 
2. Fluorescence studies 
Fluorescence spectroscopy is one of the most widely used analytical techniques in 
biochemistry and molecular biophysics, mainly due to its high sensitivity and capability 
to probe different microenvironments. Fluorescence measurements allow investigating 
the structural and dynamic properties of biomolecules or their complexes and can be 
performed in the steady-state or time-resolved modes. In the case of drug@protein 
systems, the excited state dynamics provides key information on fundamental processes 
such as energy or charge transfer, depending on the specific supramolecular 
interactions. Thus, characterisation of encapsulated singlet excited states constitutes an 
appropriate tool to investigate molecular recognition processes involved in drug 
transport, metabolism and pharmacological activity. From the emission quantum yields 
and the lifetimes of the singlet excited states of a bound ligand, it is possible to 
determine key parameters such as the stoichiometry of the complex, the binding 
constant or the degree of occupancy. Although changes in the intrinsic fluorescence 
properties of the tryptophan residues can be monitored, in this review we have focused 
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our attention on the emission behaviour of probe drugs (Chart 1) when bound to a 
protein. 
2.1. Biphenyl derivatives 
The nonsteroidal antiinflammatory drug flurbiprofen (FBP) is a 2-arylpropionic acid, 
prescribed for the relief of mild to moderately severe pain and for ophthalmic 
disorders;
40
 FBP is usually commercialised as a racemic mixture, although its 
pharmacological effect is mainly due to the (S)-enantiomer.
41 
The emission profile of 
(S)-FBP@HSA upon excitation at 267 nm, where both FBP and HSA absorb, shows a 
spectrum with contribution of the individual components. However, the fluorescence 
intensity of the complex is lower than that calculated by taking into account the 
percentage of light absorbed by each subunit and assuming no interaction.
42
 Time-
resolved measurements have been performed by fluorescence upconversion (FU) and 
time-correlated single photon counting (TCSPC). The FU kinetic traces at 310 nm 
(emission maximum of FBP) show that, beyond a few picoseconds, the decay of (S)-
FBP@HSA is slightly faster than that of (R)-FBP@HSA. This is explained in terms of a 
dynamic quenching of bound FBP, which becomes even more pronounced at longer 
time scales as revealed by TCSPC. The nature of the observed quenching has been 
attributed to a stereoselective exciplex formation and/or electron transfer process. Time-
resolved anisotropy measurements recorded by FU do not show significant 
configuration dependence for the encapsulated FBP; by contrast, the TCSPC anisotropy 
decays clearly show a chiral discrimination that can be related to the orientation of the 
drug within the protein, where the degrees of freedom for conformational relaxation can 
be more effectively restricted in the case of the (R)-enantiomer.  
 Photosolvolysis of FBP in aqueous solution gives rise to 2-(2-hydroxy-1,1’-
biphenyl-4-yl)propanoic acid (BOH) via a nucleophilic aromatic substitution.
43
 Being a 
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phenolic compound, BOH is expected to display an enhanced acid character in the first 
singlet excited state,
44
 a property that can be employed to gather information on the 
nature of the microenvironment experienced within HSA. In the presence of increasing 
amounts of HSA, (S)-BOH gives rise to a ground-state complex with a maximum at ca. 
300 nm.
45
 In neutral buffer, emission of BOH displays two maxima at 343 and 412 nm, 
attributed to 
1
BOH* and to the corresponding excited phenolate, respectively. However, 
a progressive diminution of the 412 nm band is observed upon addition of protein, 
indicating that excited state deprotonation is disfavoured within the hydrophobic HSA 
cavities (Figure 1A). A similar trend is shown by (R)-BOH, albeit to a significantly 
lower extent (Figure 1B). Displacement experiments with (S)-ibuprofen ((S)-IBP), a site 
II probe,
11
 reveal that BOH mainly interacts within this binding site. Thus, fluorescence 
spectra show that displacement of BOH by (S)-IBP from the protein to the bulk solution 
leads to a recovery of the phenolate emission. A significant stereodifferentiation is 
observed for this process. 
2.2. Naphthalenes  
Naproxen (NPX) is a photosensitising nonsteroidal antiinflammatory drug containing a 
naphthalene chromophore, whose photobehaviour has been well characterised in 
homogeneous media.
46
 Upon excitation of the (S)-NPX@HSA complex at 266 nm, 
where both protein and drug absorb, the emission profile exhibits contribution from the 
two components
47
 as well as a small but significant degree of energy transfer (EnT) 
from 
1
Trp* to NPX (Figure 2). The calculated interchromophoric distance assuming a 
FRET mechanism is ca. 24 Å. The behaviour of both (S)- and (R)-NPX within HSA or 
BSA follows similar trends. When the NPX moiety is covalently bound to a 
cyclopeptide and encapsulated within HSA, EnT from 
1
Trp* to NPX is again observed 
in the complex.
48
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 Cinacalcet (CIN) is a calcimimetic drug
49-51
 that binds almost quantitatively to 
HSA.
52
 Upon complexation, emission of CIN@HSA roughly matches the spectrum 
simulated taking into account the relative absorption of the protein and free drug 
components. Thus, no energy transfer from 
1
Trp* to CIN has been demonstrated in the 
complex.
53
 The most remarkable photophysical properties from the biological point of 
view are associated with formation of the triplet excited state and are discussed in 
Section 3.2. 
 Encapsulation of 1’-hydroxy-2’-acetonaphthone (HAN) within HSA leads to 
enhanced fluorescence intensity and lengthening of the emission lifetimes.
54
 Picosecond 
anisotropy measurements show strong confinement in the protein microenvironment. 
Efficient energy transfer between 
1
Trp* and HAN (ca. 70%) occurs in the HAN@HSA 
complex, with a calculated interchromophoric distance of 17 Å. 
2.3. Aromatic ketones  
Typically, aromatic ketones are non-fluorescent due to their high intersystem crossing 
quantum yields. However, the protein complexes of a few related compounds have been 
examined by means of fluorescence spectroscopy. This is the case of chalcones, some of 
which are flavonoids with antiinflammatory, antibacterial, antiviral, antitumor and 
antiparasitic activity.
55
 Licochalcone A (LCA) is a member of this family, whose 
interaction with HSA and BSA has been investigated.
56, 57
 In homogeneous media, LCA 
displays three absorption maxima corresponding to the neutral (382 nm), monoanionic 
(401 nm) and dianionic (457 nm) forms. In the presence of protein the spectrum is 
consistent with the predominance of the neutral LCA form and exhibits a large red shift, 
due to a strong drug-protein interaction. Enhancement of the LCA fluorescence intensity 
is accompanied by a progressive blue shift with increasing concentration of HSA or 
BSA. Time-resolved experiments reveal significant lengthening of the fluorescence 
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lifetimes upon incorporation to HSA and BSA (5 and 3 times, respectively). The 
calculated docking of LCA in domain IIA of BSA is shown in Figure 3. 
2.4. Salicylic acids 
Salicylic acid (SLA) is known for its antiinflammatory activity due to inhibition of 
prostaglandins synthesis.
58, 59
 This drug and many of its derivatives are also used for the 
treatment of skin diseases, such as inflammatory burns, psoriasis, etc.
60-62
 2-Hydroxy-4-
trifluoromethylbenzoic acid (HTB) is an active metabolite structurally similar to SLA 
derived from triflusal, a drug used in the treatment and prevention of various 
thromboembolic diseases.
63
 Upon excitation at 260 nm in the presence of HSA, the 
intrinsic protein fluorescence (max = 360 nm) is partially quenched by HTB, with a 
concomitant increase of the HTB band (405 nm), pointing to efficient energy transfer. 
This result is in agreement with expectations, taking into account the relative singlet 
state energies of Trp and HTB (96 and 80.7 kcal mol
-1
, respectively) and the 
considerable overlap between the emission of Trp and the absorption of HTB, which 
support the feasibility of a Förster mechanism.
64
  
 The bioactive compounds 3,5-dichlorosalicylic acid (DSA) and 5-chlorosalicylic 
acid (CSA) exhibit excited state intramolecular proton transfer (ESIPT), a 
photochemical process markedly influenced by the nature and strength of hydrogen 
bond interactions. This principle has found applications for the design of 
photostabilisers, solar filters, solar energy collectors, etc.
65, 66
 More importantly, ESIPT 
probes have been used as molecular reporters for the microheterogeneous environments 
provided by a variety of biological and biomimicking assemblies.
67-69
 After ESIPT, both 
DSA and CSA tautomerise to their keto form, which is the only emitting species at ~420 
nm.
70, 71
 The absorption spectra of DSA and CSA are red-shifted in the presence of 
BSA, in agreement with the hydrophobic nature of the environment.
72, 73
 Likewise, for 
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DSA@BSA a slight red-shift of the fluorescence is observed, together with a significant 
quenching. By contrast, enhanced emission of the keto form of CSA is observed within 
BSA. The binding constant (KB) values determined by the modified Stern-Volmer
74
 and 
the Benesi-Hildebrand equations,
75
 (KB < 10
3
 M
-1
) show in both cases a moderate 
binding to the proteins. Steady-state fluorescence anisotropy measurements are 
consistent with a higher degree of motional restriction in the confined environment 
provided by the protein. 
 Another SLA derivative, whose interaction with BSA has been recently 
addressed, is aurintricarboxylic acid (ATA), a red dye used as antiapoptotic drug.
76
 The 
fluorescence intensity of ATA is enhanced upon binding to BSA (KB > 10
5
 M
-1
);
77
 
accordingly, time-resolved measurements show that the average lifetime (<F>) 
increases from 1.23 ns in the bulk solution to 6.14 ns in ATA@BSA.
78
 This is attributed 
to the restricted confinement of the drug within the protein and is confirmed by steady-
state and time-resolved anisotropy measurements.  
2.5. Heterobicyclic compounds 
Isofraxidin (ISF) is a coumarin derivative with antiinflammatory and antitumor 
activity.
79
 The fluorescence intensity of ISF increases in the presence of HSA; 
Scatchard plot analysis and molecular modelling point to preferential binding to site I, 
with a constant value in the order of 10
5
 M
-1
. A similar behaviour is observed for 
formonometin (FME), a natural estrogenic compound with antioxidant properties.
80
 
Binding to HSA leads to enhancement and blue shift of its fluorescence maximum; KB 
is also in the range of 10
5
 M
-1
. As usually, fluorescence anisotropy measurements in the 
presence of HSA are in agreement with a more constrained environment provided by 
the protein cavity.  
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 Piroxicam (PIR) is a nonsteroidal antiinflammatory drug that binds to HSA at two 
sites.
81
 Singlet excited PIR decays within the protein cavities with time constants in the 
picosecond range. Upon excitation at the protein band, energy transfer from 
1
Trp* to 
PIR is observed with moderate efficiency. Fluorescence anisotropy studies indicate 
diffusion of PIR within HSA. 
 Psoralens are widely used for the treatment of psoriasis and eczema.
82
 The 
fluorescence intensity of a number of psoralens and coumarins decreases and shifts to 
the blue upon addition of HSA;
83
 this effect is more pronounced for psoralen@HSA 
than for coumarin@HSA complexes. Scatchard plots analysis evidences the existence 
of two classes of binding sites; this is further confirmed by time-resolved fluorescence 
measurements, which reveal the existence of two lifetime components in the decay 
kinetics. 
 Quinolone-like drugs are an important class of antimicrobials that produce 
photosensitivity disorders.
84-86
 An early member of this family is nalidixic acid (NAL), 
whose major vehicle in plasma is HSA.
87
 Binding of NAL to HSA or BSA occurs 
mainly at site II and results in quenching of the drug fluorescence;
88
 in addition, energy 
transfer from 
1
Trp* to NAL is observed. Fluoroquinolones (FLQs) are quinolone 
derivatives with improved pharmaco-toxicological profile.
89
 The association constants 
for binding of different FQs such as enoxacin (ENO), lomefloxacin (LOM), ofloxacin 
(OFL), norfloxacin (NOR) and ciprofloxacin (CIP) to HSA and BSA have been 
determined by fluorescence spectroscopy and range from 10
2
 to 10
5
 M
-1
.
90, 91
 In this 
context, the results obtained by chromatography, capillary electrophoresis or 
ultrafiltration are in agreement with low affinities of FLQs to serum albumins (KB < 10
3
 
M
-1
),
92, 93
 in line with recent work based on fluorescence and laser flash photolysis.
90
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2.6. Tricyclic aromatics  
Carprofen (CPF) is another example of nonsteroidal antiinflammatory drug with in vivo 
photosensitising properties.
46
 Binding of CPF to serum albumins at 1:1 molar ratio 
occurs with very favourable association constants (KB > 10
6
 M
-1
).
94
 In addition, a 
significant degree of energy transfer from 
1
Trp* to CPF is observed upon excitation at 
266 nm.
47
 This process is more pronounced for CPF@BSA than for CPF@HSA. Based 
on the FRET theory, the average donor-acceptor distance values for the EnT process are 
ca. 21 Å. No significant differences are found in the photobehaviour of (S)- or (R)-CPF 
within the protein. 
 The binding process of the water-compatible anthracene derivative 9-
anthraceneacetic acid (ANA) to HSA and BSA, as well as to HAG and BAG has been 
systematically investigated.
95
 Analysis of the UV-vis absorption spectra suggests in all 
cases formation of 1:1 complexes between ANA and proteins. Fluorescence 
measurements (exc = 367 nm) show a progressive decrease of the ANA emission 
intensity (390-470 nm) upon addition of increasing amounts of protein; this effect is 
more pronounced for ANA@HSA. However, the fluorescence lifetime of ANA in air-
equilibrated solutions (ca. 10.5 ns) does not depend on the presence of protein. The 
binding constants determined by titration of the ANA emission upon addition of protein 
are slightly higher for glycoproteins than for albumins; in the former, only one binding 
site is considered (KB ~ 2×10
6
 M
-1
), while in the latter two binding sites with different 
affinities are found (KBI ~ 10
6
 M
-1
 and
 
KBII ~ 10
4
 M
-1
). This is confirmed by 
displacement experiments with warfarin (site I probe) and IBP (site II probe). Similar 
trends are observed with the two enantiomers of 2-(9-anthracenyl)propanoic acid 
(ANP), although in this case a significant stereodifferentiation is noticed in the emission 
behaviour of the ANP@HSA complexes (Figure 4).
96
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 A related anthracene derivative (2-anthracenecarboxylic acid, ANC) gives also 
rise to complexes with HSA and BSA.
97-101
 Fluorescence measurements on equimolar 
ANC/protein mixtures reveal formation of complexes with a 1:1 stoichiometry. The 
highest affinity site for ANC is attributed to site II in both proteins; the binding constant 
is larger for HSA (KB ~ 10
8
 M
-1
) than for BSA (KB ~ 10
7
 M
-1
). At high ANC/albumin 
ratios several binding sites are populated, and in some of them more than one ANC unit 
is accommodated. This can be monitored by fluorescence spectroscopy, through an 
enhancement of the emission intensity and loss of the vibrational fine structure. These 
changes have been discussed in connection with the stereochemical outcome of ANC 
photodimerisation within the protein cavities. Time-resolved fluorescence 
measurements at low ANC/albumin ratios reveal the presence of two lifetime 
components (1.8 and 4 ns), whereas at higher ANC concentration longer components 
appear with lifetimes closer to ANC in the bulk solution (15.8 ns). Fluorescence 
anisotropy measurements are consistent with a restricted rotational mobility of ANC 
within the protein binding sites. 
 Acridine-based drugs, such as acridine yellow (ACY) and cationic proflavin 
(PFL), can be used as photosensitisers for the treatment of cancer and other diseases.
102
  
Both ACY and PFL form ground-state complexes with HSA,
103
 with association 
constants (KB ~ 10
5
 M
-1
) slightly higher for PFL than for ACY. Dynamic quenching of 
the HSA emission through EnT from Trp to PFL or ACY is accompanied by 
enhancement of the drug fluorescence; this process is more efficient for PFL@HSA 
than for ACY@HSA.  
 -Carbolines are natural products with varied biological properties, including their 
interaction with neurotransmitters and neuromodulators of the central nervous system
104
 
and their ability to photosensitise fungi, viruses or bacteria for photodynamic therapy.
105
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Harmane (HAR) and norharmane (NOR) are members of this family, whose binding 
properties to HSA and BSA have recently been addressed.
106, 107
 In neutral aqueous 
solution, NOR and HAR present two absorption maxima corresponding to the neutral 
(~348 nm) and protonated (~370 nm) species.
108
 The fluorescence intensity of 
protonated NOR (max ~450 nm) or HAR (max ~435 nm) markedly decreases upon 
addition of increasing amounts of albumins, with the concomitant enhancement of a 
new band at ~380 nm, corresponding to the neutral forms. Fluorescence measurements 
show that NOR binds more tightly to HSA (KB ~ 10
5
 M
-1
) than to BSA (KB ~ 10
4
 M
-1
); 
the association constant of HAR to BSA (KB ~ 10
3
 M
-1
) is much weaker. Fluorescence 
anisotropy studies on NOR@albumin also show a marked increase of the neutral 
species (max ~380 nm) as a result of protein binding; this effect is higher for BSA. 
2.7. Miscellaneous compounds 
The importance of ligand/protein interactions is not only limited to the study of drugs, 
but can be extended to other systems such as natural bile acids whose binding to serum 
albumins is an important step in enterohepatic circulation.
109
 Cholic acid (CHA) is one 
of the primary metabolites synthesised from cholesterol in the liver; it is in part 
conjugated to glycine or taurine and plays a pivotal role in fat digestion. A remarkable 
emission enhancement, accompanied by a hypsochromic shift of the maximum (ca. 50 
nm) is observed upon binding of several dansyl (DNS)-labelled CHA (3-DNS-CHA, 
3-DNS-CHA, 7-DNS-CHA and 7-DNS-CHA) to HSA;110 this effect is more 
marked for the C-3 regioisomers (Figure 5A, B). Two binding constants (in the order of 
10
5
 and 10
4
 M
-1
) are determined for 3- and 3-derivatives, whereas only one has been 
reported for 7- and 7-DNS-CHA (ca. 104 M-1). Moreover, the -derivatives display 
stronger binding to the protein than the -analogues. Experiments with site I and site II 
displacement probes demonstrate that 3- and 3-DNS-CHA selectively bind to site II, 
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while 7- and 7-DNS-CHA populate site I of HSA. Time-resolved measurements 
reflect a significant increase of the fluorescence lifetimes, attributed to a less efficient 
deactivation by non-radiative processes. This might be due to restrictions of the freedom 
degrees inside the HSA binding sites, where the microenvironment protects the singlet 
excited state from attack by deactivating species. The singlet decay kinetics has been 
used to determine the distribution of DNS-CHA between the bulk solution and the HSA 
binding sites; the results are in agreement with the trends observed in the steady-state 
experiments. An EnT process from 
1
Trp* to the DNS-derivatives is observed (Figure 
5C), with interchromophoric distances of 21 and 25 Å for the C-3 and C-7 regioisomers, 
respectively. Docking studies are in agreement with the different binding behaviour of 
the dansyl derivatives. Figure 6 shows the minimum energy conformation of interaction 
between 3-DNS-CHA (balls) and site 1 of HSA (sticks). 
 The fluorescence intensity and the average lifetime of the antibiotic tetracycline 
hydrochloride (TCH) increase upon binding to HSA, BSA and alkaline phosphatase 
(ALP) from Escherichia coli; this effect is higher for ALP. 69, 70, 111, 112 Quenching of 
Trp emission is observed, with concomitant enhancement of the drug fluorescence 
intensity, as a result of the EnT process. Binding constants in the 10
6
 M
-1
 range are 
determined for ALP, whereas for albumins the values are two orders of magnitude 
lower. Time-resolved anisotropy measurements point to a motional restriction of the 
drug within the protein cavity. The higher correlation time obtained for HSA suggests a 
more buried location of the drug within this protein, which is confirmed by molecular 
docking studies.  
 Squaraine dyes (SQD) are fluorescent sensors with technological and biological 
applications.
113, 114
 Binding of the parent compound as well as its tetrabromo (SQB) and 
tetraiodo (SQI) derivatives to HSA and BSA has been monitored by the absorption 
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spectral changes, characterised by large red-shifts and hypochromism.
115, 116
 The 1:1 
dye@protein complexes are formed with association constants of about 10
6
 M
-1
 for 
SQD and SQB, and ca. 10
5
 M
-1
 for SQI. The emission spectra of the dyes increase 
dramatically and shift to the red upon addition of albumins; this is accompanied by 
significantly longer lifetimes. Displacement experiments with site-specific binding 
probes evidence that SQB and SQI preferentially bind to site II, while SQD binds at 
both sites, with a marginal selectivity for site II.  
 Levosimendan (LSM) is a cardiovascular drug with a strong inotropic effect used 
for acute heart failure.
117
 Upon binding to HSA, 1:1 stoichiometry complexes are 
formed with association constants of ~10
6
 M
-1
.
118
 The UV absorption spectrum of 
LSM@HSA is red-shifted, suggesting an increase in the electronic conjugation due to a 
more planar conformation of the drug upon encapsulation. Femtosecond fluorescence 
upconversion measurements show a clear enhancement of about three times of <F> of 
LSM bound to HSA. 
 Lumichrome (LCH), the major riboflavin biodegradation product, has some 
natural biological functions,
119
 and is able to generate singlet oxygen.
120, 121
 Upon 
addition of HSA, the UV-absorption maximum of LCM (355 nm) does not show 
noticeable changes, while the emission intensity (maxima at 475 nm) decreases. Job’s 
plot analysis evidences the formation of a 1:1 complex between LCH and the protein, 
with an association constant in the order of 10
4
 M
-1
. Time-resolved anisotropy 
measurements are consistent with the heterogeneity of LCH binding to HSA, where the 
rotational relaxation time of the drug is much lower than that of the global rotational 
time of the protein. 
 Upon interaction of tropolone derivatives with anticancer effects, including 
colchicine (COL) and colchiceine (CEI) with HSA, a significant enhancement of the 
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CEI fluorescence is noticed, in contrast to the nearly negligible effect observed for 
COL.
122
 The association constant for CEI@HSA determined by fluorescence 
measurements is in the order of 10
4
 M
-1
; conversely, for COL, the estimated KB value is 
below 10
3
 M
-1
. Immobilisation of the tropolone chromophore within the specific 
binding site of the protein is assumed to be the main factor responsible for fluorescence 
enhancement, as in the interaction between COL and tubulin protein. Displacement 
experiments reveal selective binding to site II of HSA.  
3. Transient absorption spectroscopy 
Laser flash photolysis has been less exploited than fluorescence emission to investigate 
the binding of ligands to proteins, although it is also a potentially powerful tool. Here, 
we will focus on the behaviour of triplet excited states of ligands (Chart 1) generated 
upon LFP, following protein encapsulation. It will be shown that the properties of these 
transient species (especially the triplet lifetimes, T) are very sensitive to the 
microenvironment experienced within the protein binding sites. Hence, they can be 
successfully used to investigate the issue of drug binding, providing information on 
interaction strength, conformational restrictions, protection from attack by oxygen or 
other reagents, stereochemical requirements, etc. Applications of the LFP technique to 
drug/protein systems are detailed below. They include a variety of issues, such as the 
determination of drug distribution among the bulk solution and the protein binding sites, 
competition of two proteins to bind a ligand, drug-drug interactions within protein 
binding sites, enzymatic-like activity of serum albumin or determination of 
enantiomeric compositions.  
3.1. Biphenyl derivatives 
The transient absorption spectrum of (S)-FBP in PBS solution obtained after laser 
excitation at 266 nm, under air, displays a maximum at 360 nm, assigned to the FBP 
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first triplet excited state (
3
FBP*).
123
 The kinetic decay trace follows a first order 
exponential law with a lifetime (F) of 1.5 s (Eq. 1). After addition of HSA at 0.7:1 
drug/protein molar ratio, 
3
FBP* is again the only transient species detected; however, 
two monoexponential terms are necessary to fit accurately the decay trace (Eq. 2), with 
lifetimes of 11.2 (minor) and 35.9 s (major). They are ascribed to 3FBP* within site I 
(I) and site II (II) of HSA, respectively, based on the higher affinity of FBP for site 
II.
124
 To obtain independent evidence supporting this assignment, LFP experiments 
have been performed in the presence of (S)-IBP as site II-probe.
125
 Thus, addition of (S)-
IBP to the (S)-FBP/HSA mixtures results in a decreased contribution of the longest 
lifetime term, with a concomitant enhancement of the components assigned to free and 
site-I-bound FBP. For a battery of solutions at different (S)-FBP/HSA molar ratios 
(from 1.4:1 to 1:1), fitting of the decay traces contains three monoexponential terms 
(Eq. 3), supporting distribution of the drug among the two protein binding sites and the 
bulk solution. From the corresponding preexponential coefficients AF, AI and AII the 
percentage of (S)-FBP bound to different amounts of HSA or BSA can be determined. 
The distribution of (S)-FBP among the binding sites and the bulk solution is represented 
in Figure 7. At high (S)-FBP/HSA molar ratios most of the acid remains unbound, 
whereas at low (S)-FBP/HSA molar ratios site II is selectively populated. The work has 
been extended to (R)-FPB and to BSA.
123
 The most significant differences between both 
albumins are related to the dynamic ranges found for the triplet lifetimes and to the 
relative occupancy of the two binding sites. Lengthening of the T values is partially due 
to protection of 
3
FBP* from attack by oxygen when encapsulated. Thus, the rate 
constant of triplet quenching by oxygen for free (S)-FBP in PBS is 1 × 10
10
 M
-1
 s
-1
; by 
contrast, the values in site I or site II are one and two orders of magnitude lower, 
respectively. 
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 A similar study has been performed on FBP-Me, the methyl ester of FBP; the 
hydrophobic character of this prodrug favours inclusion within HSA.
126, 127
 Aqueous 
solutions containing (S)-FBP-Me and HSA (molar ratio from 10:1 to 0.5:1) give rise to 
the transient absorption spectra assigned to 
3
FBP-Me* (Figure 8A). For (S)-FBP-
Me/HSA ratios between 1:1 and 0.5:1, the signal follows a second-order exponential 
decay with lifetimes of 31.5 and 4.1 s. Based on the higher affinity of 2-arylpropionic 
acids methyl esters for site I,
128
 the major component under non-saturating conditions 
(with longer T) is assigned to (S)-FBP-Me within this site; consequently, the minor 
component is assigned to site II-bound FBP-Me. Independent evidence supporting this 
assignment is obtained by LFP experiments in the presence of warfarin, as site I 
probe.
129
 Thus, at 1:1:1 (S)-FBP-Me/HSA/warfarin molar ratio the contribution of the 
longer-lifetime component drops to ca. 50% (as compared with ca. 70% in the absence 
of warfarin). In the case of (R)-FBP-Me, the triplet lifetimes within site I and II are 
157.6 and 16.6 s, respectively, indicating a remarkable stereodifferentiation in the 
decay kinetics within the protein microenvironment (Figure 8B). In BSA, the most 
remarkable difference is found under non-saturating conditions; thus, for 1:1 FBP-
Me/albumin molar ratio, 20-30% of the drug remains free (compared to complete 
binding in HSA).  
 The behaviour of FBP and FBP-Me in the presence of HAG and BAG has been 
studied with a similar methodology.
130
 Only one T value clearly higher than that of free 
FBP or FBP-Me is found in the presence of glycoproteins, indicating only one type of 
binding site. The percentages of free and protein-bound ligand obtained by fitting the 
decay traces with Eq. 4 indicate that FBP binds weakly to both glycoproteins, while 
FBP-Me is more efficiently included, specifically in BAG. 
21 
 
The glucuronide FBP-Gluc is a phase II metabolite of FBP.
131
 Even at low FBP-
Gluc/HSA molar ratios, a high amount of glucuronide remains unbound to the protein, 
in good agreement with an enhanced hydrosolubility of this metabolite, which facilitates 
its elimination. No stereodifferentiation is observed in the protein-binding process, and 
only one type of microenvironment is occupied by (2S)- and (2R)-FBP-Gluc (triplet 
lifetime ca. 25 s), unlike the case of parent FBP. Displacement experiments using (S)-
IBP as specific site II probe confirm selective occupancy of this site.
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In the case of the main photoproduct of (S)-FBP in aqueous media, (S)-BOH, the 
transient absorption spectrum consists of a broad band centred at 380 nm, attributed to 
3
BOH*. A dramatic enhancement of the triplet lifetimes within HSA has been observed 
(19.0 s, compared with 1.3 s in bulk PBS).45 The study has also been performed with 
(R)-BOH, and no stereodifferentiation has been noticed in this case. 
 A new methodology for a rapid and reliable assessment of drug distribution 
between two proteins present simultaneously in a biological medium is based on 
determination of the relative contributions of the triplet lifetimes components obtained 
from the decay curves in the presence of serum albumin/glycoprotein binary systems.
130
 
Thus, the decay traces obtained at 360 nm for a FBP(Me)/serum albumin/glycoprotein 
mixtures at 1:0.5:0.5 molar ratio are fitted assuming that four different kinds of triplets 
can be present (Eq. 5). They are ascribed to FBP(Me) free, bound to glycoprotein and 
within site I or site II of albumins. The results show that albumins are always the major 
carriers for FBP; whereas in the case of FBP-Me, BAG competes favourably with BSA 
when both proteins are present in the same medium.  
 Determination of enantiomeric compositions, based on transient absorption 
spectroscopy, has also been achieved by exploiting the stereodifferentiation of triplet 
lifetimes within serum albumins for chiral recognition.
133
 The procedure involves LFP 
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of a series of solutions containing mixtures of the (S)- and (R)-enantiomers (percentages 
from 0:100 to 100:0) in the presence of equimolar amounts of the appropriate serum 
albumin (see Figure 9A for FBP-Me in the presence of HSA). To obtain accurate 
fittings, it is assumed that four different kinds of triplets are present, ascribed to (R)- and 
(S)-FBP-Me within site I and site II (Eq. 6). Assuming that the ratios AI
S
/ AII
S
 and AI
R
/ 
AII
R
 remain constant, fitting of the decay traces leads to the percentage of both 
enantiomers. A plot of the LFP-determined against known real values for FBP-Me in 
HSA (Figure 9B) clearly validates the proposed methodology. Chiral discrimination in 
the triplet lifetimes of the drug/protein complexes is the only requirement for the 
successful application of this LFP-based methodology, which may not be fulfilled in a 
number of systems.
133
 For example, the triplet lifetimes of (S)- and (R)-FBP in the 
presence of HSA are too close, and hence the obtained values for the percentages of the 
two enantiomers are not reliable. The problem can usually be circumvented by choosing 
another protein where the triplet lifetimes of the two enantiomers are different enough. 
For FBP, bovine serum albumin (BSA) provides an appropriate chiral selector. Thus, 
when the decay traces obtained in the presence of BSA for different (S)-FBP/(R)-FBP 
ratios are processed as before, good correlations are found between the LFP determined 
and the real enantiomeric compositions. 
The LFP technique has also proven to be a powerful tool for in situ determination of 
the glucuronidase activity of HSA. This has been achieved by monitoring the hydrolysis 
of two steroisomeric flurbiprofen glucuronides back to parent FBP.
132
 The FBP-
Gluc/HSA mixtures are incubated during regular time intervals at 37 ºC; regression 
analysis to fit the triplet decays leads to a set of four lifetimes (for free and bound FBP-
Gluc and for FBP within site I and site II, see Eq. 7).  
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3.2. Naphthalenes 
 
Naphazoline (2-(1-naphthylmethyl)imidazoline, NPZ) is a sympathomimetic agent with 
alpha adrenergic activity. After LFP of NPZ (exc = 308 nm, N2) in the presence of 
BSA, protein-bound 
3
NPZ* is detected at 410 nm, with a lifetime of ca. 170 s.134  
 The excited states of the (R)-enantiomer of CIN have been characterised in order 
to obtain relevant information about its complexation with HSA.
53
 Upon LFP of (R)-
CIN@HSA (exc = 308 nm, air), naphthalene-like triplet excited states are generated, 
with maxima at 420 nm. The corresponding decays are satisfactorily fitted using a 
function containing two monoexponential terms, corresponding to a short-lived (8 s) 
and a long-lived (37 s) components different from the value found in pure PBS (1.9 
s), indicating that the drug is incorporated into two different binding sites of HSA. 
Estimation of the KB by LFP at λexc = 266 nm leads to an average value in the order of 6 
× 10
5
 M
-1
. From the intensity of the triplet signal immediately after the laser pulse, an 
intersystem crossing quantum yield of 0.56 is determined for (R)-CIN@HSA. To 
investigate triplet quenching by oxygen in the protein microenvironment, (R)-
CIN@HSA has been submitted to chemical deoxygenation by addition of sodium 
sulphite. Despite the long triplet lifetimes of the complex, the rate constant of quenching 
by oxygen (5.4 × 10
7
 M
-1 
s
-1
) is 2 orders of magnitude lower than that determined in the 
bulk solution, which is due to the relative slower diffusion rates in the 
microheterogeneous system. As a consequence, the singlet oxygen quantum yield inside 
the protein is nearly negligible, while its value is Δ = 0.35 in homogeneous aqueous 
media. The main finding after encapsulation is that the protein microenvironment 
protects the drug from attack by oxygen, preventing the phototoxic effects caused by 
formation of singlet oxygen. This results in an enhanced photosafety of the drug. 
Interestingly, (R)-CIN exhibits also a significant affinity towards glycoproteins, where 
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the drug is located in the only existing binding site, with triplet lifetimes of 15 s 
(HAG) and 20 s (BAG). The studies have been extended to (S)-CIN, which exhibits 
somewhat different triplet lifetimes. 
 Likewise, upon LFP at 308 nm of (S)- or (R)-propranolol (PPN, a non-selective 
beta blocker used for the treatment of hypertension), the transient spectrum shows 
contributions due to 
3
PPN* and the radical cation (PPN
+˙).135 From the decay traces 
monitored at 420 nm under aerobic conditions, their lifetimes have been determined as 
1.9 and 13.5 s, respectively. The spectra in the presence and in the absence of 
albumins are almost coincident, which is in good agreement with negligible PPN 
binding to these proteins. However, in the presence of glycoproteins, the kinetics are 
markedly different: the decay traces lengthen and require a function containing three 
monoexponential terms (Eq. 8) for a satisfactory fitting, corresponding to two free 
species (
3
PPN* and PPN
+˙) plus the longer lived protein-bound triplet. Regression 
analysis of the decay curves for different PPN/glycoproteins mixtures leads to the 
preexponential factors and hence to the amount of free and bound PPN. A remarkable 
species dependence is observed for both PPN enantiomers, with a clearly higher binding 
capability in the case of the bovine protein. Thus, at 1:1 drug/protein molar ratio a 45% 
of (R)-PPN is bound to HAG, while in the case of BAG this value is 76%. 
 Nabumetone (4-[6-methoxy-2-naphthy1]-2-butanone, NAB) is a neutral 
nonsteroidal antiinflammatory drug. It binds to serum albumins and acts as prodrug, 
being metabolised by the liver to 6-methoxy-2-naphthylacetic acid, the active 
pharmacological form.
136
 After LFP (exc = 337 nm, N2) in the presence of BSA, bound 
3
NAB* is detected, with a lifetime of ca. 700 s.137 No other transients are observed. 
Binding to HAG and BAG has also been investigated after LFP at 308 nm under air; 
protein bound 
3
NAB* decays with a T value of 16.6 in HAG and 25.8 s in BAG.  
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 The photobehaviour of (S)- and (R)-NPX in the presence of HSA or BSA has been 
investigated by LFP at 308 nm in PBS/air.
130
 The transient spectrum in the absence of 
protein shows the main maximum at 440 nm (
3
NPX*, 1.8 s) and a weaker band in the 
550-650 nm range (NPX
+˙). However, in the presence of sufficient amounts of 
albumins, only 
3
NPX* is observed, with the kinetic traces at 440 decaying at longer 
timescales. At 1:1 molar ratio, a satisfactory fitting is obtained considering two 
monoexponential terms (Eq. 2), whereas at higher drug/protein ratios, three lifetime 
values are necessary to obtain a good fitting of the decay signal (Eq. 3). This is ascribed 
to the presence of two long-lived NPX@HSA species, in addition to free NPX. From 
the decay curves for NPX/protein ratios from 1:0.15 to 1:1 the values of the 
preexponential coefficients are determined, corresponding to free, site-I bound, and site-
II-bound drug. By contrast, a different behaviour is observed in the presence of HAG or 
BAG, where the binding degree is markedly lower.
130
 Thus, with equimolar amounts of 
glycoproteins, two triplet lifetimes are found (Eq. 4), corresponding to free and bound 
drug. Regression analysis of the decay curves leads to the binding degree. Remarkable 
species dependence for both NPX enantiomers is noticed, with a clearly higher binding 
capability displayed by the bovine protein. Thus, at 1:1 drug/protein molar ratio a 19% 
of (S)-NPX is bound to HAG, while in the case of BAG this value is 57%. 
 The interaction between HSA and two bioconjugates, which contain (S)- or (R)-
NPX covalently bound to a cyclopentapeptide with an arginine-glycine-aspartate 
sequence (cRGD), has also been studied using LFP.
48
 The results have been compared 
with those obtained for appropriate models. Excitation of NPX-cRGD bioconjugates at 
266 nm, under air, leads to the NPX triplet, with monoexponential decays (T ca. 60 s) 
which strongly agrees with selective binding to one site.  
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 Three drugs containing the naphthalene chromophore, (NPX, PPN, and CIN) but 
with different affinities toward albumins and glycoproteins, have been employed for the 
assessment of drug distribution in binary protein systems, using a similar methodology 
as in the case of FBP and FBP-Me.
135
 Upon LFP of NPX, PPN and CIN in the presence 
or absence of proteins, the naphthalene triplet excited state at 420 nm is always 
detected, although the decay kinetics is structure-, medium- and species dependent. 
Experiments performed in both human (HSA/HAG) and bovine protein media 
(BSA/BAG) show that when two proteins are present simultaneously in the same 
medium, fitting of the decay traces is clearly consistent with a distribution of the drug 
between the different biological compartments and the bulk solution, which correlates 
well with the known protein affinities of each drug. The results demonstrate that 
albumins are the major carriers for NPX, whereas PPN binds preferentially to 
glycoproteins. An intermediate situation is found for CIN, which presents comparable 
affinity for both types of proteins (see Figure 10 for (R)-CIN)). The two enantiomers of 
each drug exhibit similar trends, although a small stereodifferentiation is observed 
between the triplet lifetimes in the protein binding sites. 
 The feasibility of drug-drug interactions (DDI) within the binding sites of 
transport proteins has been probed, using drug pairs (CIN/PPN and CIN/NAB) 
complexed within HAG or BAG.
137
 The concept involves detection of triplet-triplet 
energy transfer (TTEnT), which requires a close proximity between the donor and 
acceptor partners and can only occur within a common biological compartment. In the 
absence of glycoproteins, the drug mixtures are not soluble in PBS and give rise to 
turbid suspensions. Complexation of CIN/PPN and CIN/NAB with glycoproteins is 
easily followed by naked eye, through a complete solubilisation that leads to clear 
preparations. When a solution of CIN/PPN/HAG at 1:1:1 molar ratio is submitted to 
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LFP (exc = 308 nm, air), the decay trace monitored at 450 nm matches with that of the 
CIN/HAG system, with no contribution from 
3
PPN* in the kinetic decay. A similar 
situation is observed in the presence of BAG. Likewise, for the CIN/NAB/glycoprotein 
systems, the decay traces at 450 nm are identical to those of the CIN/glycoprotein 
mixtures, and 
3
NAB* does not contribute to the kinetic decay. These results clearly 
indicate an efficient energy transfer from 
3
PPN* or 
3
NAB* to CIN and reveal the 
occurrence of DDI between drugs that share a common protein binding site (see 
illustration of the concept in Figure 11). As the TTEnT process is completed within the 
duration of the laser pulse (< 20 ns), deactivation of the excited triplet states is 
extremely fast, with a rate constant higher than 5 × 10
7
 s
-1
. Such a high value is not 
compatible with the expectedly slow diffusion inside the protein binding sites and 
points to formation of pre-associated complexes between donor (PPN or NAB) and 
acceptor (CIN). This is confirmed by theoretical calculations, which combine atomistic 
and quantum-semiempirical methodologies (see optimised geometry in Figure 12). 
3.3. Aromatic ketones  
Ketoprofen (KPF) is a nonsteroidal antiinflammatory drug used for arthritis-related 
inflammatory pain.
138
 After LFP at exc = 355 nm of KPF in the presence of BSA or 
HSA the transient absorption spectra exhibit two main bands at 320-330 and 530 nm, 
which decay in the microsecond time domain with two monoexponential terms.
139, 140
 
For BSA, in deaerated solutions, the short lifetimes (assigned to 
3
KPF*) are 0.26 s for 
(S)-KPF and 0.34 s for (R)-KPF. This is remarkable, since the triplet lifetime in neutral 
aqueous solution falls in the picosecond range.
141, 142
 In HSA, 
3
KPF* is believed to 
abstract hydrogen from the protein matrix, generating ketyl radicals (max = 330 and 540 
nm). 
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 To study the influence of microheterogeneous media on the electronic 
configuration of the triplet excited state, 4,4-dimethoxybenzophenone (DMB) has been 
encapsulated in HSA.
143
 Thus, aqueous solutions containing DMB and HSA (molar 
ratio from 1:0 to 1:5) in neutral PBS buffer have been submitted to LFP. The DMB 
transient absorption spectrum obtained after excitation at λexc = 355 nm in the presence 
of HSA is similar to that obtained in acetonitrile, but different from that recorded in 
PBS solution. The spectral shape modifications upon addition of HSA point to a 
reequilibration between ππ* and nπ* triplets within the lipophilic protein cavities. 
Moreover, HSA complexation leads to clear changes in the decay traces up to 1:2.5 
molar ratios. The decay kinetics, monitored at 430 nm in air-equilibrated solutions, fit 
well with three lifetimes of 0.45, 1.4, and 14.4 μs. The shortest-living component is 
associated with the presence of free DMB in the bulk solution, previously determined in 
PBS. The other two longer lifetimes are correlated with the existence of two HSA-
bound species. Addition of oleic acid and ibuprofen as displacement probes confirms 
assignment of the 14.4 and 1.4 μs components to DMB within site I and site II, 
respectively. 
 Laser excitation (355 nm) of the flavonoid-derivative licochalcone A (LCA) in Ar 
saturated PBS leads to weak and broad transient absorption band in the 550-580 nm, 
region, which decays monoexponentially with a lifetime of 2.4 s.56, 57 In the presence 
of equimolar HSA the decay kinetics is biexponential, with lifetimes of 0.9 and 6.0 s. 
This is explained as 
3
LCA* being present in the two sites of HSA involved in 
complexation. A similar behaviour is observed in BSA.  
3.4. Salicylic acid derivatives 
The molecular basis of photoallergy mediated by HTB has been investigated following 
the interaction between this drug metabolite and HSA by LFP (exc = 308 nm).
64
 The 
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results are consistent with complexation of HTB to site I of HSA. The HTB transient 
spectrum in PBS displays a maximum at 500 nm, attributed to the excited triplet state, 
together with the solvated electron at 690 nm. In the presence of an equimolar 
concentration of HSA (under air) only the T-T absorption is observed, with a triplet 
lifetime of 12 s, which is considerably longer than in PBS (0.6 s). According to the 
kinetic data, HTB binding to HSA is nearly complete at 1:1 molar ratio, and only one of 
the two protein binding sites is occupied. For site assignment, oleic acid and ibuprofen 
have been employed to displace HTB; the data are consistent with preferential binding 
of HTB to site I. 
3.5. Heterobicyclic compounds 
Quenching of the triplet excited states of the antimalarial drug quinine (QIN) has been 
observed in BSA and attributed to the effect of Trp. By contrast, in the case of the 
analogous drug quinacrine (QIC), the triplet excited state is only slightly quenched by 
BSA, and no appreciable spectral changes are detected.
144
 
 Transient absorption measurements have been used to assess whether excitation 
(355 nm) of coumarin- or psoralen-HSA complexes results in any net photochemistry.
83
 
At high HSA/substrate ratios the amount of uncomplexed substrate is minimised. For 
oxygen saturated 6,7-DMC (dimethoxycoumarin)/HSA in aqueous buffer, a transient at 
500 nm is observed, decaying over a timescale of 5 s; it can be assigned either to the 
triplet excited state in a site that is not accessible to oxygen or to a tryptophan-derived 
radical generated by trapping of the initial coumarin radical cation. For 5,7-DMC and 
4'-amino-4,5',8-trimethylpsoralen (ATM) in HSA, similar transient species at 500 nm 
for oxygen-saturated solution and a stronger broader signal in the 500 nm region for 
nitrogen purged solutions are detected, but there is no evidence for radical cation 
formation. By contrast, laser excitation of 8-methoxypsoralen (8-MOP) does not give a 
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500 nm signal. These results can be explained by assuming that the triplet absorbs at 
shorter wavelength (<400 nm) or that the photoionisation efficiency for 8-MOP is 
considerably lower than that for the methoxycoumarins.  
 Laser flash photolysis of the quinolone derivative nalidixic acid (NAL) at 355 nm 
in neutral medium, in the presence of HSA or BSA, evidences a significant  shortening 
of the triplet lifetime (max = 630 nm), attributed to electron transfer reaction with the 
amino acid residues of the protein.
88
 Likewise, the triplet signal of NOR at 610 nm 
generated by LFP in the presence of BSA decays faster than in solution due to reaction 
with the matrix.
91
 However, independent work has found that the interaction of NOR 
and a series of related FLQs (ENO, CIP, OFL) with HSA or BSA are very weak (KB in 
the range of 10
2
).
90
 The FLQ lifetimes and quantum yields do not appear to be affected 
by the presence of albumins, pointing to their predominant presence in the bulk 
solution. 
3.6. Tricyclic aromatics  
Nanosecond LFP (exc = 308 nm, PBS/Ar) has been performed on solutions of (R)- or 
(S)-CPF with HSA (1:1 molar ratio);
94, 145
 similar T-T absorption spectra are detected 
for both CPF stereoisomers (Figure 13A), but significant stereodifferentiation is 
observed in the kinetic traces (Figure 13B). The decay dynamics shows the presence of 
two components with different lifetimes that are correlated with complexation of CPF to 
the two high-affinity albumin binding sites; the two values determined for (R)-CPF (8.9 
and 40 s) are longer than those obtained for (S)-CPF (2.3 and 24 s). The shorter 
lifetimes, for which stereodifferentiation is more important, are ascribed to 
3
CPF* in 
site I. This is attributed to electron-transfer quenching by the only Trp residue present in 
this site of the protein. The stereodifferentiation detected in the triplet decays correlates 
well with the relative reactivity in the photodehalogenation process (see Section 4). 
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Stereodifferentiation is also observed in the covalent photobinding of CPF to HSA, the 
key process involved in the onset of the clinically reported photoallergy. 
 As stated above, ANA has been employed as a water-compatible anthracene 
derivative to investigate the photophysical behaviour of this chromophore upon binding 
to proteins.
95
 While LFP of ANA at exc = 355 nm in PBS/air gives rise to several 
transient species (benzylic-type radical, radical anion, triplet excited state, radical cation 
and hydrated electron), in the presence of one equivalent of protein only the triplet 
excited state is detected (maximum at 420 nm). The triplet lifetime lengthens 
considerably (up to 50-fold) in the protein media. The presence of two binding sites in 
albumins is associated with the kinetic evidence for two different triplet lifetimes; the 
major, longer-lived component under non-saturating conditions is assigned to site II, 
while the minor component corresponds to site I. By contrast, only one T value is found 
within glycoproteins, where only one binding site is available for ANA. 
 A parallel study has been performed on (S)- and (R)-ANP as chiral reporters for 
their binding to proteins.
96
 As in the case of ANA, ANP shows a very complex transient 
absorption spectrum in aqueous solution (Figure 14A); however, for the ANP@protein 
complexes, only the band attributed to the lowest triplet excited state is observed 
(Figure 14B). Under aerobic conditions, the triplet lifetimes of both enantiomers, 
monitored at 420 nm, are markedly longer in the protein media. In the case of albumins, 
two distinct intraprotein microenvironments are revealed by two different triplet 
lifetimes; their assignment is based on quenching by the Trp residue at site I of the 
albumins. Thus, the longer lifetime in the presence of albumins is ascribed to ANP 
located in site II, while the shorter one is safely assigned to ANP within the Trp 
containing site I. By contrast, only one lifetime is needed to fit the decays in the 
presence of glycoproteins, indicating only one binding site. As regards the accessibility 
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of oxygen to ANP in protein media, the triplet quenching constants by oxygen are in the 
range 10
7
-10
8
 M
-1 
s
-1
, markedly lower than in solution and site-dependent (Figures 14C, 
D). 
 Rose bengal (RBG) is a widely used singlet oxygen sensitiser. Association of this 
dye to HSA leads to a noticeable decrease in the rate of 
3
RBG* quenching by oxygen 
(one order of magnitude).
146
 This result implies that excited triplets are bound to high 
affinity sites that are relatively protected from oxygen coming from the external 
medium. This protection reflects a low solubility and/or mobility of O2 inside the 
protein and implies that the excited triplet remains incorporated to the protein and is not 
expelled to the surrounding solvent during its lifetime. 
3.7. Miscellaneous compounds 
 When LFP of the antiarthritic and anticancer drug COL (exc = 355 nm) is 
performed in aqueous media, in the presence or absence of HSA no transient species is 
detected.
147
 Selective irradiation of COL in aqueous medium at long wavelength (350 
nm) leads to photoisomerisation to -lumicolchicine (-LCL) as major product, together 
with minor amounts of -LCL, irrespective of the presence or absence of protein. After 
LFP of irradiated COL/HSA and COL/BSA mixtures, long-lived (>10 s) transient 
species are detected, with absorption maxima at ca. 370 and 600 nm, assigned to the 
3
LCL*@albumin complexes. Interestingly, LFP of - and -LCL in aqueous solution in 
the absence of protein does not give rise to any detectable transient species. Laser 
excitation of colchiceine (CEI) in buffered aqueous medium does not generate any 
transient either, in agreement with the results obtained for COL and LCL. However, in 
the presence of HSA, transient absorption spectra very similar to those of 
3
COL* in 
acetonitrile are recorded.
148
 The LFP experiments confirm a very low binding affinity of 
COL to HSA (KB lower than 10
3
 M
−1
) compared to CEI (KB > 10
4
 M
−1
). 
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 The halogenated squaraine dyes SQB and SQI have been submitted to laser flash 
photolysis (exc = 532 nm) in the presence of HSA.
116
 The triplet lifetimes are much 
longer than to those determined in buffer, pointing to an efficient encapsulation of the 
dyes within HSA. 
4. Intraprotein photoreactivity 
The use of proteins as supramolecular systems to influence the course of organic 
photoreactions has attracted increasing interest over the last two decades. The well-
defined 3D structure of serum albumins, with identification of the binding pockets, has 
been particularly useful to anticipate the capability of these proteins to interact with a 
large number of ligands. Specifically, the photoreactivity of encapsulated substrates can 
be modified by providing protection from attack by oxygen or other external reagents, 
by imposing conformational restrictions in the binding pockets, or by influencing the 
stereochemical outcome through the supply of a chiral source. In this context, special 
attention has been paid to asymmetric photochemistry or photochirogenesis as a new 
tool for the preparation of enantiomerically enriched compounds. A selected group of 
examples (Chart 1) demonstrating the potential of protein hosts to modify the course of 
organic photoreactions are presented below. 
 The first example of supramolecular photochirogenesis using a protein as 
supramolecular host is enrichment in the (R)-antipode after irradiation of racemic 1,1´-
bi-2-naphthol (BNP).
149-152
 In the presence of BSA an enantiomeric excess (ee) of 99 % 
is observed after a conversion yield of 77 %.
151
 This high ee has been explained on the 
basis of different protein binding properties of the (R)- and (S)-enantiomers. 
Interestingly, (S)-BNP@BSA exhibits a more intense UVA band than its (R)-
counterpart, attributed to its presence as naphtholate. Hence, the reported ee has been 
mainly associated with the higher absorption of (S)-BNP@BSA at the irradiation 
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wavelength. In addition to the kinetic resolution arising from decomposition, 
photoinversion of (S)-BNP@BSA to (R)-BNP@BSA also contribute to the obtained 
results, albeit to a lesser extent. Interestingly, a species-dependent photobehaviour is 
observed, with HSA performing less efficiently (46% ee, 65% conversion) than BSA, 
under the same conditions.
150
 
 Stereodifferentiation in the photolysis of drugs within protein matrix has received 
little attention with only two examples reported until now.
94, 139, 145, 151, 153
 Ketoprofen 
(KPF) exhibits a medium dependent photochemistry.
46
 In organic solvents, it presents 
the typical benzophenone photoreactivity, while in neutral aqueous medium an efficient 
photodecarboxylation takes place from the carboxylate anion. The latter process is 
triggered by intramolecular electron transfer from the carboxylate group to the excited 
carbonyl, yielding 3-ethylbenzophenone as main product.
46
 In serum albumins, 
photodecarboxylation is still the main pathway but it occurs with a considerably lower 
quantum yield than in water,
139, 153
 and only a low (BSA) or insignificant (HSA) optical 
enrichment in (S)-KPF is observed upon photodestruction.
151
 In competition with 
photodecarboxylation, photobinding of KPF to the proteins has been reported.
139, 154, 155
 
This is interesting from the photobiological point of view, as covalent photoadduct 
formation is in the origin of the clinically reported photoallergy.  
 Serum albumin-mediated stereodifferentiation has also been observed in the 
photochemistry of CPF.
94, 145
 By contrast with KPF, photodecarboxylation is in this case 
a minor reaction pathway, so the CPF chiral centre is conserved during the 
photoreaction. The prevailing photochemical process is cleavage of the C-Cl bond that 
yields a dehalogenated photoproduct (PPF). 
94, 145
 As stated above (Section 3.6), the 
stereodifferentiation observed for triplet lifetimes correlates well with the 
photodegradation kinetics, which is faster for (S)-CPF@HSA. Irradiation of CPF alone 
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in PBS leads to bleaching of the fluorescence band, due to polymerisation; by contrast, 
enhanced emission is observed for (R)- and (S)-CPF@HSA. This is attributed to 
formation of PPF, whose emission quantum yield is 6 times higher than that of CPF and 
is 10 nm blue-shifted (Figure 15A). Accordingly, chiral HPLC analysis of the 
photolysates shows formation of (S)-PPF 1.5 times more efficient than that of (R)-PPF 
inside the protein (Figure 15B). In addition, photobinding to HSA occurs with 
efficiency somewhat higher for the (R)-isomer (Figure 15A, inset).
94, 145
 
 In this context, it is important to underline that albumins have been extensively 
investigated as model systems for drug-induced photoallergy, an immunological 
response triggered by formation of a covalent photoadduct between a protein and a 
photosensitising drug. In addition to the abovementioned KPF and CPF, a number of 
drugs have demonstrated photobinding capability.
156  
In this context, a detailed study 
has been performed with HTB in the presence of proteins, to elucidate the mechanism 
involved in photoadduct formation.
157
 In addition to prove photobinding to BSA after 
sephadex filtration, it has been established that the -NH2 group of lysine is involved in 
the photoreaction. Accordingly, irradiation of HTB in the presence of poly-L-lysine also 
leads to photoaddition by nucleophilic attack of the free amino group to the 
trifluoromethyl moiety (Figure 16).
64
 
 The [4+4] photocyclodimerisation of the achiral ANC gives rise to four 
regioisomers (Figure 17), namely the anti- and syn-head-to-tail (HT), and the anti- and 
syn-head-to-head (HH). Among them, only syn-HT and anti-HH are chiral compounds.  
 The photodimerisation rate is retarded in the presence of BSA.
99
 More 
interestingly, complexation of ANC with BSA affects the HT/HH ratio. Indeed, in the 
absence of protein, the HT isomers are predominantly formed, whereas encapsulation 
within BSA inverts the regioselectivity and favours formation of the HH products. It has 
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been proposed that HH dimerisation is more difficult in the bulk solution due to 
electrostatic repulsion between the negatively charged carboxylate moieties; however, 
within BSA this is counterbalanced by interactions between the ANC molecules and the 
cationic amino acid residues, leading to enhanced HH dimerisation.
99
 Furthermore, BSA 
provides a chiral source that has a marked influence on the stereoselectivity of syn-HT 
and anti-HH dimers formation from achirals ANC, which have been obtained with 
moderate enantiomeric excess.
99, 100
 In this context, the photochirogenic properties of 
the different binding sites have been investigated using nitromethane as quencher of the 
ANC singlet excited state.
100
 The presence of nitromethane results in an increase of the 
ee of syn-HT, with the concomitant decrease of that of anti-HH. These data combined 
with the fluorescence results (see Section 2.6), suggest that the stereoselectivity is site-
dependent. A similar study has been performed with HSA as host.
98, 101, 158
 In this case, 
the protein-mediated photocyclodimerisation ensues with enhanced HT dimers 
formation. Moreover, remarkably higher ee are obtained up to 79 and 88% for syn-HT 
and anti-HH, respectively. It is noteworthy, that the same enantiomer of anti-HH is 
preferentially formed in both albumins, while the antipodes are favoured in the case of 
syn-HT.
98-101, 158
 
To expand the range of biomolecular hosts, the [4+4] photocyclodimerisation of 
ANC has been investigated in the presence of a molecular chaperone protein, the 
archaeal prefoldin from Pyrococcus horikoshii OT3 (PFD).
159
 In the presence of PFD, 
similar conversions are obtained as in the bulk solution. In addition, a moderate 
decrease of the HT-dimers is noticed and only a marginal ee is achieved for the syn-HT 
and anti-HH dimers. These results point to a higher mobility of ANC in the PFD 
binding sites than in those of serum albumins. Nonetheless, protein encapsulation still 
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allows alignment of two ANC molecules leading to HH dimers, which are sterically and 
electrostatically disfavoured in solution. 
 Photodimerisation of anthracene inside albumins requires the use of high ligand to 
protein ratios. However, under non-saturating conditions it is unlikely that two 
anthracene units are found within the same binding site, so this process is prevented and 
other reaction channels are opened.
95, 96
 In this context, photooxidation of ANA has 
been examined using different transport proteins such as HSA, BSA, HAG and BAG at 
1:1 molar ratio.
95
 Irradiation of aerated PBS solutions of ANA yields anthraquinone as 
product. This photooxidation process occurs through a triplet-triplet energy transfer 
from 
3
ANA* to molecular oxygen, generating singlet oxygen (
1
O2). This species reacts 
with ANA by a formal [4+2] cycloaddition to the central anthracene ring; 
rearrangement of the resulting endoperoxide followed by cleavage of the 9-substituent 
leads to anthraquinone. Under these conditions, photooxidation is markedly slower than 
in PBS solution; the most remarkable result is found for serum albumins, where the 
reaction rate constant is one order of magnitude lower. This indicates that the protein 
cavities provide an important protection towards photooxidation, which is attributed to a 
slower diffusion of oxygen inside the protein.  
 A dramatic stereodifferentiation in the photooxidation process has been found in 
the related (S)- and (R)-ANP.
96
 For instance, in the presence of HSA the reaction rate 
constant is higher for the (S)-enantiomer, leading to a kinetic resolution with 
enhancement of the less reactive (R)-ANP (ee of ca. 34% after 120 min of irradiation). 
From a mechanistic point of view, involvement of singlet oxygen in the photooxidation 
is confirmed by the remarkable acceleration of reaction rates in D2O, in agreement with 
the longer lifetime of 
1
O2 in this medium. Overall, the retarded photooxidation within 
the protein binding sites is in good agreement with the lower rate constants obtained for 
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quenching of encapsulated 
3
ANP* by oxygen (see Section 3.6). Further experiments 
using selectively excited photosensitisers that are not present in the same 
microenvironments as ANP demonstrate that photooxidation is compartmentalised.  
 Unimolecular processes do not require diffusion of the reactants, so they appear 
particularly suitable to evaluate the influence of intraprotein microenvironments on 
photoreactivity. With this aim, the Norrish type II fragmentation of 1,1-(4-tert-
butylbenzoyl)-(4´-methoxybenzoyl)butane, also known as propylavobenzone (PAB), 
gives rise to clean generation of avobenzone (ABZ).
160
 Since ABZ is a widely used 
UVA filter in sunscreens, PAB can be considered as a pro-filter. Formation of ABZ can 
be monitored by steady-state UV-Vis spectrophotometry, through the appearance of an 
absorption band with maximum at 355 nm. In the LFP experiments, the transient 
absorption band corresponding to 
3
PAB* at max = 400 nm is initially observed (Figure 
18); formation of ABZ from this precursor is detected by the appearance of the 
abovementioned maximum at 355 nm, which does not decay in the microsecond 
timescale (Figure 18). The reaction kinetics is slower in the presence of HSA, where the 
quantum yield is 2.8 times lower (R = 1.4 × 10
-2
) than in acetonitrile. A satisfactory 
correlation is found between the decreased PAB photoreactivity and the increased 
3
PAB* lifetime when encapsulated in the protein. This suggests that the conformation 
required for intramolecular abstraction of the -hydrogen by the excited carbonyl is 
disfavoured within the confined HSA microenvironment.  
 The classical photo-Fries rearrangement has also been used as a probe reaction to 
evaluate the influence of serum albumins of different species (HSA, BSA and rabbit 
serum albumin, RSA) as microheterogeneous media.
161
 In this context, 4-methoxy-1-
naphthyl hydrogen glutarate (MNG) and the analogous acetate (MNA) are chosen 
because of their selective interaction with albumins in site II and site I, respectively. Site 
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assignment is established by fluorescence displacement experiments using dansylamide 
and dansylglycine as specific probes. The photo-Fries rearrangement of MNG and 
MNA proceeds via homolytic cleavage of the naphthyloxy-carbonyl bond from the 
singlet excited state and leads to formation of ortho-acyl naphthols after in cage 
recombination of the radical pairs. The presence of HSA significantly affects the 
quantum yield of photoproduct formation, which decreases in the case of MNG from ca. 
0.16 in PBS down to ca. 0.06 within the protein. Moreover, the photoproduct is formed 
2.3 times more efficiently for MNA than for MNG, which supports a site-dependent 
reactivity of the intraprotein photorearrangement. Concerning the influence of the 
albumin species, the quantum yields of photoreaction within BSA are enhanced but the 
difference between the two binding sites is less pronounced. Interestingly, the same 
result has been determined for both substrates within RSA, which is compatible with the 
existence of only one common binding site in this protein.  
 Oxidative photocyclisation of N-methyldiphenylamine (DPA) is an interesting 
reaction that occurs through a multistep pathway involving two consecutive triplet 
excited states (Figure 19A).
162
 Hence, the short-lived triplet excited state (
3
DPA*), 
generated after excitation and intersystem crossing undergoes an adiabatic ring closure, 
leading to the N-methyl-4a,4b-dihydrocarbazole triplet excited state (
3
DHC*). This 
species crosses to its ground state (DHC) and undergoes dehydrogenation in the 
presence of molecular oxygen, giving rise to N-methylcarbazole (MCZ) as final 
product. By contrast, under anaerobic conditions DHC ring-opens back to the starting 
DPA.
162
 Interestingly, oxygen plays a dual role in this photoreaction. On the one hand, 
it quenches the amine triplet excited state disfavouring MCZ formation; on the other 
hand, it is required as a reagent for the final DHC oxidation. The efficiency of DPA 
photocyclisation is maximised within the albumin binding sites. The photocyclisation 
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quantum yields are markedly enhanced in the presence of serum albumins (Figure 19B). 
It is noteworthy that the highest efficiency is obtained for oxygen-saturated solutions of 
DPA@BSA, which is very close to the upper limit imposed by the intersystem crossing 
quantum yield of DPA (0.8-0.9) (Figure 19A). Detailed information on the involved 
processes is obtained by LFP monitoring the 610 nm traces of ground state DHC. In 
aerated PBS, the decay follows a first order exponential law with a lifetime of 15 s. 
Encapsulation of DPA within albumins is associated with the presence of two lifetime 
components (15 and 451 μs for HSA, or 15 and 384 μs for BSA). These data, together 
with site displacement experiments, show that at DPA/serum albumin 1:1 molar ratio, 
ca. 90% of the substrate is complexed within site I of the protein. The observed 
behaviour is associated with the slow intraprotein diffusion of oxygen that leads to 
inefficient quenching of the short-lived 
3
DPA*@serum albumin. Finally, the 610 nm 
intermediate is quenched by oxygen with a rate constant in the range of 10
5 
M
-1
 s
-1
, ca. 2 
orders of magnitude lower than oxygen diffusion within protein binding site I. This 
explains why the final dehydrogenation of DHC to MCZ is not affected by 
complexation. 
Finally, the enantioselective 6 electrocyclisation of a family of photochromic 
bis-thienylethenes (BTE), namely 1,2-bis(2,5-dimethyl-3-
thienyl)hexafluorocyclopentene (BTE-1),  1,2-bis(2-hydroxymethyl-5-methyl-3-
thienyl)hexafluorocyclopentene (BTE-2) and 1,2-bis(5-hydroxymethyl-2-methyl-3-
thienyl)hexafluorocyclopentene (BTE-3) has also been carried out inside HSA.
163
 For 
the three compounds, the ring closing reaction results in formation of two enantiomers. 
In general, the highest conversion ratio and ee have been obtained at high 
HSA/substrate molar ratios.
163
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5. Summary and Outlook 
Binding to proteins plays an important role in the pharmacological activity, 
biodistribution and metabolism of drugs. Drug@protein supramolecular assemblies can 
be advantageously investigated by photophysical methods (noteworthy steady-state and 
time-resolved fluorescence, as well as transient absorption spectroscopy) when the 
drugs of interest contain a photoactive chromophore. This approach is particularly 
useful when such chromophore can be selectively excited at long wavelengths, where 
the aromatic amino acids of the proteins do not absorb. Since singlet and triplet excited 
states exhibit strongly medium-dependent properties, they can be used as reporters to 
probe the microenvironments defined by protein binding sites. Specifically, the 
fluorescence quantum yields and lifetimes provide key data to determine the 
stoichiometry of the complex, the binding constant, the lipophilicity of binding sites and 
the relative degrees of occupancy of the different compartments. In addition, transient 
absorption spectroscopy leads to formation of encapsulated triplet excited states, a 
process which is strongly favoured over generation of ionic species (i. e. radical ions). 
The resulting 
3
drug*@protein entities display photophysical properties that can be 
successfully used to gather information on interaction strength, conformational 
restrictions, protection from attack by external agents, etc. Interestingly, the triplet 
lifetimes of protein-complexed drugs are remarkably long (even under aerobic 
conditions), providing a broad dynamic range for identification of distinct triplet 
populations or for chiral discrimination. 
 The use of proteins as supramolecular hosts modifies the photoreactivity of 
encapsulated substrates by controlling the traffic of reactants between the bulk solution 
and the intraprotein microenvironments, by imposing conformational restrictions in the 
binding pockets, by making use of the amino acid residues as active centers, or by 
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supplying a chiral source that influences the stereochemical outcome. As a proof of the 
concept, the potential of proteins as hosts capable to modify the course of organic 
photoreactions has been demonstrated in selected examples that include 
decarboxylation, dehalogenation, dimerisation, rearrangement or cyclisation, among 
others. 
 On the basis of the existing knowledge, there is clearly room for future work on 
photoactive drug@protein assemblies. Thus, the use of triplet excited states as reporters 
can be further developed to exploit the specific advantages of these species, in particular 
the broader dynamic range, the possibility to investigate relatively slow processes (for 
instance, relocation), and the unambiguous information provided on direct interactions 
that need a close contact between the involved partners (collisions), free from 
interferences associated with processes operating at longer distances (i. e., FRET). As 
regards the use of protein binding sites as nanoreactors for photochemical processes, the 
next step forward seems the design of photocatalytic systems, which would be possible 
when the binding constants of the reactants are substantially higher than those of the 
photoproducts. In addition, the reaction in the bulk solution should be minimised, for 
instance by achieving selective excitation of the complexes. Ideally, the protein binding 
sites should play an active role, working not only as constraining cavities but also 
contributing to the catalytic process with participation of the active centers provided by 
the amino acid residues. 
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Figures and Figure Legends 
 
 
 
 
 
 
 
 
Figure 1. (A) Fluorescence spectra (normalised at the short-wavelength maximum) of (S)-BOH 
in PB  (λexc = 308 nm, air, 10
−4
 M) after addition of increasing amounts of HSA. The (S)-
BOH/HSA molar ratios are 1:0 (black), 1:0.2 (blue), 1:0.4 (red), 1:0.8 (magenta), and 1:2 
(green). (B) Plot of the fluorescence intensity at 409 nm vs HSA/BOH molar ratio for (S)-BOH 
(black) and (R)-BOH (red). Adapted with permission from J. Phys. Chem. B, 2012, 116, 14839-
14843. Copyright 2012 American Chemical Society. 
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Figure 2. Fluorescence spectra of HSA, BSA, (S)-NPX, (S)-NPX/HSA and (S)-NPX/BSA 
(complexes at 1:1 molar ratio). All the experiments were carried out in PBS/air. The absorbance 
of the samples is 0.1 at the excitation wavelength (266 nm). This corresponds to concentrations 
in the order of 10
-5
 M. Adapted with permission from Chem. Phys. Lett., 2010, 486, 147-153, 
Copyright 2010 Elsevier. 
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Figure 3. Docking of LCA in domain IIA of BSA. Reproduced from Ref. 57 with 
permission from the European Society for Photobiology, the European Photochemistry 
Association, and The Royal Society of Chemistry. 
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Figure 4. Fluorescence spectra of ANP in the presence of increasing amounts of HSA, up to a 
1:1.5 molar ratio for (A) (R)-ANP and (B) (S)-ANP. Adapted with permission from Org. Lett., 
2011, 13, 3860-3863. Copyright 2011 American Chemical Society. 
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Figure 5. ( ) Emission spectra (λexc = 340 nm) of 3β-DNS-    in PB  (10 μM) upon addition 
of increasing concentrations of HSA (0-50 μM). (B)  hanges in the relative fluorescence 
quantum yield (rel = /0) of all DNS derivatives plotted against the HSA concentration with 
the corresponding fittings. ( ) Emission spectra of     in PB  (20 μM) upon addition of 
increasing amounts of 3β-DNS-    (up to 20 μM). The dashed line corresponds to a blank 
experiment with the highest guest concentration in the absence of    , λexc = 290 nm. Adapted 
with permission from J. Phys. Chem. B, 2011, 115, 10518-10524. Copyright 2011 American 
Chemical Society. 
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Figure 6. Minimum energy conformation of interaction between 3-DNS-CHA (balls) 
and site 1 of HSA (sticks). Reprinted with permission from J. Phys. Chem. B, 2011, 115, 
10518-10524. Copyright 2011 American Chemical Society. 
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Figure 7. Percentage of free (white), site I- (violet) and site II-bound (red) (S)-FBP in the 
presence of HSA at different (S)-FBP/HSA ratios.
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Figure 8. Laser flash photolysis (exc = 266 nm) of 2.5 × 10
-5
 M FBP-Me (black), as well as 1:1 
solutions of (S)-FBP-Me/HSA (green) and (R)-FBP-Me/HSA (blue) in 0.01 M PBS, under air. 
(A) Spectra obtained 3.7 s after the laser pulse. (B) Normalised decays monitored at 360 nm. 
Adapted with permission from J. Am. Chem. Soc., 2005, 127, 10134-10135. Copyright 2005 
American Chemical Society. 
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Figure 9. (A) Normalised decays ( = 360 nm) for several (S)-FBP-Me/(R)-FBP-Me/HSA 
mixtures: 1:0:1 (black), 0.7:0.3:1 (blue), 0.3:0.7:1 (red), and 0:1:1 (green) after LFP at 266 nm. 
(B) LFP-determined values against known real values, together with the linear fit of the 
experimental points. Adapted with permission from Chem. Eur. J., 2008, 14, 11284-11287. 
Copyright 2008 Wiley. 
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Figure 10. Decays for (R)-CIN (10
-4
 M, PB  0.01 M, p  = 7.4, λexc = 266 nm, λem = 420 nm, 
air) in the presence of human proteins. Inset: distribution of (R)-CIN in the different 
compartments, determined from the preexponential factors of the fitting curves. Adapted with 
permission from J. Phys. Chem. B, 2011, 115, 4460-4468. Copyright 2011 American Chemical 
Society. 
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Figure 11. Representation of the use of TTEnT to detect DDI between two drugs sharing a 
common protein binding site. Laser flash photolysis (exc= 308 nm, PBS/air) of CIN/PPN 
systems. Normalised spectra and decay traces (λmax = 450 nm) for CIN/HAG (black), PPN/HAG 
(blue) and CIN/PPN/HAG (orange). The concentration of each component is 5.8 × 10
-4
 M. 
Adapted with permission from J. Phys. Chem. Lett., 2013, 4, 1603-1607. Copyright 2013 
American Chemical Society. 
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Figure 12. Optimised geometry of PPN and CIN within the binding site of HAG. Adapted with 
permission from J. Phys. Chem. Lett., 2013, 4, 1603-1607. Copyright 2013 American Chemical 
Society. 
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Figure 13. (A) Transient absorption spectra obtained 5 s after the laser pulse (exc = 308 nm) 
and (B) decays monitored at 450 nm of anaerobic buffered solutions of equimolar mixtures of 
(R)-CPF/HSA (blue) and (S)-CPF/HSA (black). Adapted with permission from J. Am. Chem. 
Soc., 2004, 126, 9538-9539. Copyright 2004 American Chemical Society. 
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Figure 14. Laser flash photolysis in PBS, under air at exc = 355 nm. Transient absorption 
spectra of (S)-ANP in the absence (A) and in the presence of HSA, at 1:1 molar ratio (B), 
recorded 1 μs and 2.9 μs after laser pulse, respectively.  tern-Volmer plots for quenching of the 
(S)-ANP triplet state by oxygen in site I (C) or in site II (D) of HSA. Adapted with permission 
from Org. Lett., 2011, 13, 3860-3863. Copyright 2011 American Chemical Society. 
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Figure 15. (A) Fluorescence spectra (exc = 320 nm) of aerated (S)-CPF/HSA (black) and (R)-
CPF/HSA (blue) at a molar ratio of 1 before (dash line) and after (solid line) UVA irradiation. 
Inset: photobinding of CPF enantiomers with HSA monitored by fluorescence after UVA 
irradiation and subsequent sephadex filtration. (B) Formation of PPF enantiomers upon UVA 
irradiation of racemic CPF@HSA. Adapted with permission from J. Phys. Chem. B, 2007, 111, 
423-431. Copyright 2007 American Chemical Society. 
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Figure 16. Photobinding of HTB to poly-L-lysine. 
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Figure 17. Photoproducts resulting from the [4+4] photocycloaddition of ANC. 
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Figure 18. Laser flash photolysis spectra of PAB@HSA (molar ratio of 1; 2.5 × 10
-4
 M) in 
aerated PBS registered 0.5 s (black) and 40s (blue) after the 308 nm laser pulse. Reproduced 
from Ref. 160 with permission from the European Society for Photobiology, the European 
Photochemistry Association, and The Royal Society of Chemistry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
300 400 500 600 700
0.00
0.02
0.04
0.06
0.08

A
 (
a
. 
u
.)
 Wavelength (nm)
 
72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. (A) Diagram of the reaction mechanism with the structures of N-
methyldiphenylamine (DPA), N-methyl-4a,4b-dihydrocarbazole (DHC), and N-methylcarbazole 
(MCZ). (B) CBZ concentration plotted as a function of irradiation time for DPA free in 
acetonitrile (8.25 × 10
-5
 M) and encapsulated in HSA or BSA (at DPA/SA molar ratio of 1) 
under aerated or oxygen bubbled conditions. Adapted with permission from Org. Lett., 2012, 14, 
1788-1791. Copyright 2012 American Chemical Society. 
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Equations 
F(-t/τ )
0 FΔA=ΔA +A ×e       Eq. 1 
I II(-t/τ ) (-t/τ )
0 I IIΔA=ΔA +A ×e +A ×e      Eq. 2 
F I II(-t/τ ) (-t/τ ) (-t/τ )
0 F I IIΔA=ΔA +A ×e +A ×e +A ×e    Eq. 3 
F B(-t/τ ) (-t/τ )
0 F BΔA=ΔA +A ×e +A ×e      Eq. 4 
F I II B(-t/τ ) (-t/τ ) (-t/τ ) (-t/τ )
0 F I II BΔA=ΔA +A ×e +A ×e +A ×e +A ×e   Eq. 5 
S S R R
I II I II(-t/τ ) (-t/τ ) (-t/τ ) (-t/τ )S S R R
0 I II I IIΔA=ΔA +A ×e +A ×e +A ×e +A ×e   Eq. 6 
FBP-Gluc FBP-Gluc FBP FBP
F B I II(-t/τ ) (-t/τ ) (-t/τ ) (-t/τ )
0 F B I IIΔA=ΔA +A ×e +A ×e +A ×e +A ×e  Eq. 7
 
T T RC
F B F(-t/τ ) (-t/τ ) (-t/τ )T T RC
0 F B FΔA=ΔA +A ×e +A ×e +A ×e    Eq. 8
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Modification of the drug excited state properties within proteins provides information 
on binding and may result in a different photoreactivity. 
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